By studying identical twins, researchers have identified mechanisms that could be behind the development of type 2 diabetes…. The study involved 14 pairs of identical twins in Sweden and Denmark. One of each twin had type 2 diabetes while the other was healthy. Emma Nilsson, the researcher who carried out …
Read More »EASD: Non-albuminuric CKD in Type 1 Diabetes Patients Increasing
Researchers are unsure why the phenotype is increasing but suggest that more effective treatments may be contributing to the increase in non-albuminuric CKD…. Chronic kidney disease (CKD) is a common complication of diabetes associated with glomerular filtration rate (GFR) loss. Normally, before the GFR loss occurs, albuminuria will be detected. …
Read More »EASD: Type 2 Diabetes plus Ischemic Heart Disease Can Predict Mortality
Long-term mortality of patients with ischemic heart disease is independently predicted by diabetes…. Anna Norhammar, MD, PhD, of the cardiology unit in the department of medicine at Karolinska Institutet in Sweden, said during her presentation, “Diabetes is common among patients with heart failure that report ischemic heart disease and it’s …
Read More »Exercise May Not Reduce Type 2 Diabetes Risk as Much in People with Increased Genetic Risk
“An interaction of genetic risk with physical activity on incident type 2 diabetes that appears to be driven principally through genetic risk to insulin resistance.”… Yann C. Klimentidis, PhD, of the University of Arizona Mel and Enid Zuckerman College of Public Health in Tucson, and colleagues wrote, “It has been …
Read More »Liraglutide (Victoza) Provides Good Control with Less Hypoglycemia for MODY
Besides sulfonylureas, GLP-1RA can also be a treatment option for HNF1A diabetic patients…. Maturity-onset diabetes of the young adults (MODY) is responsible for 1-2% of all cases of diabetes. HNF1A diabetes is caused by loss of B-cell functions. It is usually misclassified as type 1 diabetes due to common hyperglycemic …
Read More »No Mortality Reduction in Type 2 Diabetes with Tight Glycemic Control
No effect of tight glycemic control on mortality or major cardiovascular events in long-term follow-up of the ADVANCE trial…. The Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE study) assessed the effects of routine blood-pressure lowering and strict glucose control in a broad cross …
Read More »Update: Islet Cell Transplantation for the Treatment of Type 1 Diabetes
Promising trial showed safe restoration of near-normoglycemia in type 1 diabetes…. Islet transplantation is a well-established therapeutic treatment for a subset of patients with difficult to control type 1 diabetes mellitus. Before the Edmonton Protocol, only 9% of the 267 islet transplant recipients since 1999 were insulin independent for more …
Read More »Standing Desks Could Combat Childhood Obesity
Changing the type of desks students use in schools could impact the health of our nation…. Obesity is a big concern and some adults are opting to use standing desks in favor of their standard office chairs as a way to avoid sitting during long hours at work, believing that …
Read More »Stanley Schwartz, MD, FACP, FACE: Introduction, ADA 2014
Dr. Stanley Schwartz introduces himself briefly and talks about how much he enjoying his “working retirement” and actually get more academic work done since he left academia. He also says that he is “having great fun taking care of my patients and advacning the ideas I come up with as …
Read More »Stanley Schwartz, MD: A New Way of Classifying Diabetes – The Beta-Cell Centric Approach
Dr. Stanley Schwartz talks about his groundbreaking presentation at the 2014 ADA in which he outlined a new approach to classifying diabetes based on the health of the patient’s beta-cells. He explains in detail here how the current system of classification is full of contradictions and overlap between different types …
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.